Anticancer Agents (Cancer Chemotherapy)

Author(s):  
Prasan Bhandari
2011 ◽  
Vol 2011 ◽  
pp. 1-9 ◽  
Author(s):  
Astha Varma ◽  
Harish Padh ◽  
Neeta Shrivastava

Plant-derived natural products occupy an important position in the area of cancer chemotherapy. Molecules such as vincristine, vinblastine, paclitaxel, camptothecin derivatives, epipodophyllotoxin, and so forth, are invaluable contributions of nature to modern medicine. However, the quest to find out novel therapeutic compounds for cancer treatment and management is a never-ending venture; and diverse plant species are persistently being studied for identification of prospective anticancer agents. In this regard,Andrographis paniculataNees, a well-known plant of Indian and Chinese traditional system of medicines, has drawn attention of researchers in recent times. Andrographolide, the principal bioactive chemical constituent of the plant has shown credible anticancer potential in various investigations around the globe.In vitrostudies demonstrate the capability of the compound of inducing cell-cycle arrest and apoptosis in a variety of cancer cells at different concentrations. Andrographolide also shows potent immunomodulatory and anti-angiogenic activities in tumorous tissues. Synthetic analogues of the compound have also been created and analyzed, which have also shown similar activities. Although it is too early to predict its future in cancer chemotherapy, the prologue strongly recommends further research on this molecule to assess its potential as a prospective anticancer agent.


2015 ◽  
Vol 93 (1) ◽  
pp. 33-38 ◽  
Author(s):  
Tianxiao Zhao ◽  
Yun Song ◽  
Baomin Liu ◽  
Qianqian Qiu ◽  
Lei Jiao ◽  
...  

The overexpression of P-glycoprotein (P-gp) in tumors leads to multidrug resistance (MDR), which is a significant obstacle in clinical cancer chemotherapy. The co-administration of anticancer drugs and MDR modulators is a promising strategy for overcoming this problem. Our study aimed to explore the reversal mechanism and safety of the MDR modulator LBM-A5 in vitro, and evaluate its pharmacokinetics and effects on doxorubicin metabolism in vivo. We evaluated an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay of anticancer agents mediated by LBM-A5, the effect of LBM-A5 on rhodamine123 intracellular accumulation, and the efflux in K562/DOX cells to investigate the reversal mechanisms of LBM-A5. The results showed that LBM-A5 inhibits rhodamine123 efflux and increases intracellular accumulation by inhibiting the efflux pump function of P-gp. Furthermore, the therapeutic index and CYP3A4 activity analysis in vitro suggested that LBM-A5 is reasonably safe to use. Also, LBM-A5 (10 mg/kg body mass) achieved the required plasma concentration in sufficient time to reverse MDR in vivo. Importantly, the LBM-A5 treatment group shared similar doxorubicin (DOX) pharmacokinetics with the free DOX group. Our results suggest that LBM-A5 effectively reverses MDR (EC50 = 483.6 ± 81.7 nmol·L−1) by inhibiting the function of P-gp, with relatively ideal pharmacokinetics and in a safe manner, and so may be a promising candidate for cancer chemotherapy research.


1970 ◽  
Vol 8 (4) ◽  
pp. 13-16

Cancer chemotherapy, unlike antimicrobial chemotherapy, is not based on absolute metabolic differences between cancer cells and normal human cells. Anticancer agents inhibit the growth of cells, whether normal or malignant, though different types of cell vary in their susceptibility to these agents, and in their capacity for recovery. The usefulness of these drugs is thus limited by their effects on normal cells.


1993 ◽  
Vol 17 (2) ◽  
pp. 123-129 ◽  
Author(s):  
Fran�ois Doz ◽  
Norbert Roosen ◽  
Mark L. Rosenblum

1973 ◽  
Vol 3 (1) ◽  
pp. 32-39 ◽  
Author(s):  
Shigeru Fujimoto ◽  
Takeyoshi Miyoshi ◽  
Yasumasa Nomura ◽  
Tateo Akao ◽  
Bunji Itoh ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document